Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Abbott reported Beta-CORRECT data showing its WGS-based Oncodetect test achieved 72.2% sensitivity for colorectal cancer recurrence within two years of surgery, versus 42.2% for the WES test—a 30-percentage-point improvement from a single post-surgery blood draw. Patients with detectable ctDNA had a 10.6-fold higher recurrence risk and 36.2% two-year disease-free survival, compared with 92.3% for ctDNA-negative patients. The findings support the test’s prognostic value; the test has not been cleared or approved by the FDA.

Analysis

The investable signal is clinical differentiation, not a near-term earnings inflection for Abbott. Greater sensitivity could expand use of post-surgical MRD testing, but sensitivity alone does not establish clinical utility: the release does not provide specificity, positive predictive value, or evidence that acting on results improves outcomes. More detection could also increase confirmatory testing and treatment, with associated cost and false-positive concerns.

Commercial capture is uncertain. The release links Oncodetect to Abbott’s cancer-care portfolio, while stating that Genomic Health’s laboratory performs the test; verify ownership, revenue attribution, reimbursement and ordering economics before assigning meaningful value to ABT. Its non-FDA-approved status and the need for external validation are adoption and regulatory gates. Cologuard’s screening channel is not automatically a distribution advantage for oncology MRD, where clinicians, payers and treatment decisions differ.

Over 1–3 months, independent peer-reviewed data and payer/provider response matter more than the conference announcement. Over 6–18 months, longitudinal evidence that MRD-guided care changes adjuvant treatment or outcomes is the key catalyst. Natera and Guardant Health are relevant MRD competitors; broader adoption could benefit the category, but could also intensify pricing and evidence competition. Contrarian view: the higher sensitivity headline may overstate commercial value if additional detections do not change management. For diversified Abbott, treat as optionality, not a thesis-changing catalyst.

Key Decisions for Investors

• No event-driven ABT trade on this announcement alone; the evidence is promising but does not establish incremental revenue, reimbursement or improved patient outcomes.
• Put Oncodetect on a commercial diligence watchlist: confirm who captures test revenue, payer coverage and pricing, ordering volumes, and whether results alter treatment decisions.
• Reassess the MRD category after independent validation and longitudinal data, with particular attention to specificity, positive predictive value and outcomes for patients whose ctDNA is detected only by the more sensitive assay.
• Falsifiers: weak external replication, poor reimbursement or adoption, regulatory constraints on the testing model, or evidence that additional detections do not change care; stronger evidence of treatment-guiding utility would support a more positive view.